New combo aims to tackle tough rectal cancer
NCT ID NCT07383285
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding radiotherapy and two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy and bevacizumab can improve outcomes for people with a specific type of metastatic rectal cancer (RAS-mutant/MSS). About 106 participants will be randomly assigned to receive either the standard treatment or the enhanced combination. The main goal is to see if the new combo increases the chance of living without the cancer growing for at least 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iparomlimab and Tuvonralimab (immunotherapy), radiotherapy, capecitabine, bevacizumab, oxaliplatin
- What this could lead to
- If successful, this could offer a more effective first-line treatment option for people with a hard-to-treat form of metastatic rectal cancer, potentially slowing disease progression.
- What could go wrong
- This is an early phase 2 trial with only 106 participants, so results may not apply to everyone. Adding radiotherapy and immunotherapy could increase side effects without improving outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RAS-MUTANT/PMMR METASTATIC RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.